Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Andrew D Oxman a Health Services Research Unit,
National Institute of Public Health, Postboks 4404 Nydalen, 0403, Oslo,
Norway, b UK Cochrane
Centre, Oxford OX2 6HE, c Trout Research and Education Centre at Irish Lake, Markdale,
ON, Canada N0C 1H0 Correspondence to: A D Oxman andrew.oxman{at}labmed.uio.no
A year ago BMJ Publications released a 350 page tome that
many people will regard as the last word on informed consent to treatment.1 What is missing from this otherwise
comprehensive compendium is a practical guide for clinicians at the
coalface. In an effort to overcome this deficit we have generated a
menu of alternative styles of informed consent. The first five options relate to consent for treatment within randomised controlled trials, and the final six are options for use in routine clinical practice. We
are confident that our menu will help frontline clinicians and patients
in practice. It may also help medical ethicists in theory.
Human sacrifice randomised controlled trial consent
Commercial randomised controlled trial for multicentre fun and
profit consent
American consent to randomised controlled trial treatment for the
40 million uninsured
Randomised controlled trial consent for stockholding
investigators
Kilgore Trout randomised controlled trial consent
Customary consent
Summary points
Many alternative styles of informed consent to treatment exist,
along with much theory, a few principles, and different standards of
consent within and outside randomised trials, but concise practical
advice about the available alternatives is not readily accessible
We have assembled a menu of options to help frontline clinicians and
patients to select whichever form of consent meets their particular
needs and circumstances
![]()
Consent to treatment within randomised controlled trials
Top
Consent to treatment within...
Consent to treatment in...
References
"The research ethics committee that approved this trial on
your behalf would like you to know that future generations might (or
might not) appreciate it if you would put your life at risk by joining
this trial. Although we will keep your individual trial results
confidential (especially if they run contrary to our hypothesis) and
you are free to insist on conventional treatment or withdraw at any
time, let's face it
you are a human guinea pig. The investigators
responsible for the study may have conducted a systematic review of
relevant previous studies to see whether one of the alternative
treatments has already been shown to be superior, but this sort of
evidence is beyond the interest and competency of our local research
ethics committee, which is primarily interested in protecting the host
institution from lawsuits should we accidentally kill you along the
way. The study results may or may not be submitted for publication,
depending on whether they will advance the careers of the investigators
and improve the sponsor's market share; but you may be long gone by
then anyway."
"We would like you to participate in a treatment trial of a new
drug. We really don't know much about it because we didn't write the
protocol and the trial is being run by a for-profit contract research
organisation (since their future business depends on achieving
favourable results for their sponsors, we're confident that this trial
will turn out the way they want it to). We've joined the study because
we will receive a bounty of several thousand dollars for recruiting you
into it, plus a big bonus if we can talk a dozen of you into it by the
end of the month. The drug we are testing is a trivial (but patentable)
modification of a generic drug from the same class. We don't really
expect it to perform any better, but we're pulling for
`non-inferiority' and a tiny but statistically significant difference
in unimportant side effects. We'll be able to use that result in a
series of direct to consumer television ads, so that future
unsuspecting patients will demand this exorbitantly priced, me-too drug
from their physicians. Of course, if the results do not favour the new
drug, we will bury them without trace."
"This trial is the only way we can provide health care for
uninsured Americans. We promise you free drugs and high quality care
during the trial, but may have to abandon you as soon as our grant runs out."
"I own stock in the company that manufactures this treatment, so
it must be good. Why else would I have invested so much in the company
that manufactures it?"
"Because we are uncertain about the relative merits of the
treatment alternatives for your condition, we suggest that the best
option for you is to be treated as a participant in a properly
controlled comparison. Because we're deeply concerned about your
safety and that of other patients who take part in randomised
controlled trials, we subjected the oft heard `human guinea pig'
charge to a review of studies that compared the outcomes of patients
treated within randomised controlled trials with those of similar
patients treated outside such studies.2 To our surprise, the great majority of the evidence shows that patients treated within
controlled trials have better outcomes (including mortality). When we
included this reassuring information in the proposed informed consent
portion of our submission to our local ethics committee, they initially
told us that we couldn't give you this information because providing
you with the information constituted `coercion.' However, after a
public debate in which we accused the ethics committee of unethical
behaviour in not bothering even to attempt to overcome their massive
ignorance about this evidence, they reversed their decision and now
permit us to tell you the truth about what is known."
![]()
Consent to treatment in routine clinical
practice
Top
Consent to treatment within...
Consent to treatment in...
References
"Here's a prescription, Ms Jones. Let me know if you have any
troubles."

(Credit: SUE SHARPLES)
Alternative forms of standard consent to treatment
The following can be reproduced and attached to the patient's
chart: "My colleagues, lawyers, accountants, and I are careful to
obtain the consent of all our patients to treatment. After carefully
considering your needs, my needs, my financial aspirations (and
possibly your preferences), I suggest you consent to treatment X
because (tick all that apply):
"I was taught this treatment at medical school 30 years
ago, and since it's the most time honoured treatment for your
condition, it must be the best."
"It's the newest treatment for your condition, so it must
be the best."
(To avoid confusion, we advise that only one of the foregoing reasons
is offered to a particular patient about the same treatment.)
"It's the most expensive treatment for your condition, so
it must be the best. Why else would I have bought so much stock in the
company that manufactures it?"
"A famous movie star/professional athlete/politician wrote
a heart warming endorsement of this treatment in Readers'
Digest last year. Indeed, Mrs Reagan's astrologer recommends it."
"I get a kickback from the manufacturer every time I
stick one of these gizmos into a patient."
"This drug's manufacturer pays for pizza at our
lunchtime conferences, and the pens they distribute are very reliable."
"This drug's manufacturer has given me a hand held
computer that's full of all the latest drug prescribing information (they update it on line every month), and it even writes my
prescriptions for me. Moreover, I've just learnt that the software
they use to update my computer also secretly downloads my prescriptions for the previous month, and I don't want to appear ungrateful by
prescribing products made by their competitors."
"Carruthers, who is a member of my lodge, told me
that his company makes the kit, and I feel it's only right to support a fellow freemason."
"My medical school/hospital has sold out to the firm
that manufactures this drug. They give us huge grants for our research programmes, and we give them first call on any discoveries we make.
Their stockholders may vote this money to somebody else if our
prescribing behaviour threatens their bottom line."
"I am indebted to the company that makes this
drug
not just for first class travel and accommodation at some very
enjoyable conference holidays during the conference season but also for paying me huge fees for lecturing about their drugs in a way that minimises their shortcomings and warns against other drugs in their class."
This is not an exhaustive list of options, but we are confident that it
provides readers with a starting point from which they can mix and
match and generate additional alternatives.
American emergency consent to treatment
"Before we can operate on you, our lawyers insist that you sign
this piece of paper. You may request a magnifying glass to read the
fine print. A charge for this will be added to your bill. If you have
received narcotics to relieve your pain before signing this form,
please indicate this on pages 12, 21, and 54. If you are still in
severe pain, you may rip up pages 56 to 75 and chew on page 76. A
charge for this will be added to your bill. If you would like to
consult a lawyer before signing this form, we have a highly paid staff
of lawyers on call who can assist you. Charges for this service are
listed on pages 77 to 80. If you would like to know what the evidence
is that the procedure will help you, we would be happy to tell you
about our excellent experience with patients just like yourself.
Fortunately, no one has ever conducted a proper evaluation of this
procedure, so our excellent experience is the best available evidence.
Trust us. If you would like to question our excellent experience, we would be happy to call a taxi for you. If you are currently
unconscious, aphasic, illiterate, unable to communicate in English, or
uninsured, please get out of our emergency room at once."
Cultural imperialism consent to treatment
"I must insist that you tell the patient's family members and
the village headman that they must leave the consulting room. They have
no part to play here. Although it may be customary for these people to
be involved in treatment decisions in your culture, the superior
ethical position we have developed in Western culture is that the
primacy of the individual is recognised in all things
apart from
corporate power, that is. After receiving detailed documents that he or
she is unable to read about treatment options and effects, the patient
must sign (or make some sort of mark on) the treatment contract. This
contract will be unambiguously between the patient and the corporation
for which I work. Because the customer is always right, it is important
that the patient should shoulder the responsibility for treatment
decisions. That way, the patient can take the blame if the treatment
doesn't work. If this way of securing consent to treatment is
unacceptable in your culture, I am not prepared to enter into the
contract. To do so would risk professionally damaging public criticism
from ethicists who have made the rules in my culture."
Patients' rights consent to treatment
"If you expect me, as your patient, to accept the treatment you
are prescribing for me, it is only fair that I inform you about my
requirements. Firstly, I expect you to have consulted systematic
reviews of reliable evidence about the relative merits and demerits of
the various treatment alternatives available to me. And don't try
telling me that you have decided to ignore that evidence because the
people in the research studies weren't very like me. That's an
admission that all research is irrelevant because it was all done in
the past and all done on other people. I'll only accept a specific
argument that the research evidence is clearly irrelevant to me and my
circumstances. If you give me a treatment that has been shown to be
harmful in a high quality systematic review, I will sue you, even
though I am British. If, after considering my needs and preferences,
you are uncertain about the relative merits of the treatment options
available to me, I expect you to invite me to participate in a
randomised comparison. This is because I am aware of the evidence
suggesting that people treated within randomised controlled trials do
better than others, so that I can hedge my bets in the face of this
uncertainty, and to increase the chances that I will benefit from
reduced uncertainty in future as a result of the evaluation. None of
the foregoing is to suggest that I expect you to behave like an
unthinking, insensitive automaton in responding to my request for your
help. On the contrary, I expect you to use the clinical skills,
judgment, and intangible personal resources that characterise a
thoughtful, reflective, evidence based practitioner. But I thought I
should make my position clear because I can't abide the arrogance of those doctors who continue to maintain that systematically assembled research evidence is irrelevant to them and their patients."
Interactive, personalised approach to informed consent
"Good morning Mrs Jones, my name is Dr Smith. Please sit down
and make yourself comfortable. Your general practitioner has probably
explained to you that he has asked me to see you because your
breathlessness doesn't seem to be getting any better, and he wondered
whether I might be able to suggest ways of helping. I hope I will be
able to do so, but this may well mean seeing you on several occasions
over the next few months and working together to find the best
treatment for your condition.
| |
Acknowledgments |
|---|
We are grateful to Jan Chalmers, Brian Haynes, and Robert Levine for helpful comments on earlier drafts of this paper.
Contributors: AO, IC, and DS all contributed equally and will all act as guarantors.
| |
Footnotes |
|---|
Funding: None.
Competing interests: DS has been wined, dined, supported, transported, and paid to speak by countless pharmaceutical firms for over 40 years (see bmj.com).
Potential competing interests for
DLS appear on bmj.com
| |
References |
|---|
|
|
|---|
| 1. | Doyal L, Tobias JS, eds. Informed consent in medical research. London: BMJ Publications, 2000. |
| 2. | Trout Research and Education Centre. How do the outcomes of patients treated within randomised control trials compare with those of similar patients treated outside these trials? http://hiru.mcmaster.ca/ebm/trout/ (accessed 1 Sep 2001). |
(Accepted 1 November 2001)
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+